Podcasts about t sport

Sportovní senzace, jakou český klubový sport dlouho nezažil. Basketbalistky ZVVZ USK Praha vyhrály Euroligu, nejlepší soutěž basketbalových klubů v Evropě. K triumfu je dovedla trenérka Natália Hejková, která oznámila konec své 38 let dlouhé a úspěšné trenérské kariéry. Jak cesta k titulu vypadala? A co basketbal s koncem legendární trenérky ztrácí?Host: Tomáš Budka - sportovní komentátor ČT Sport Článek a další informace najdete na webu Seznam ZprávySledujte nás na sociálních sítích X, Instagram, Threads nebo Bluesky. Náměty a připomínky nám můžete psát na e-mail zaminutusest@sz.cz

V neděli skončila olympiáda v Paříži. Slavné hry, jako skoro vždy, nebyly jen o sportu, ale taky celé řadě kulturně válečnických klání a palčivých sociálních otázek. O dějinách olympijského hnutí jsme si v Kolapsu povídali se sportovními novináři a autory podcastu Olympijský mýtus Martinem Vaitem ze serveru Sport.cz a Vojtěchem Jírovcem z ČT Sport. Podpořte vznik dalších dílů podcastu. Bez vás to nepůjde: https://www.darujme.cz/projekt/1209879 ► Máte otázku nebo se chcete podělit o názor? Napište přímo redaktorům na kolaps@denikalarm.cz ► podcasty Alarmu nahráváme ve studiu Mr. Wombat ► sound mix Ondřej Bělíček ► znělka Jonáš Kucharský

(16.7.2024) Sú dni kedy nie je čas odtrhnúť oči od obrazovky. A sú takisto také dni, kedy sa všetko podstatné udeje v posledných 3 kilometroch. Etapa s finišom v Nîmes bola práve z druhej spomenutej kategórie. O posledný regulérny šprintérsky duel medzi Biniamom Girmayom s Jasperom Philipsenom, obral divákov pád Eritrejca pred métou posledného kilometra. Philipsen vyrovnal mikrosúboj na 3:3 a súboj najlepšieho šprintéra rozuzlí zelený dres. O 16. etape a oživenej zelenej zápletke sa Adam ako hosť Velo Fokus podcastu ČT Sport rozprával so Sašou Tinkovou a Vojtěchom Jírovcom. Video verziu podcastu nájdete na Youtube ČT sport Velo Fokus na Spotify Diskutujte s nami na Discorde!

(4.7.2024) Najjednoznačnejšie a občas aj najnudnejšie etapy Tour de France vyhráva Dylan Groenewegen. Potvrdilo sa to aj dnes, v miernej opici z rekordu Marka Cavendisha, kde sa za celý deň nevytvoril únik a v jednom momente bol líder pretekov izolovaný v samostatnej skupine. O 6. etape a tiež o nadchádzajúcom Giro d'Italia Women sa Filip ako hosť Velo Fokus podcastu ČT Sport rozprával so Sašou Tinkovou a Petrom Musilom. Video verziu podcastu nájdete na Youtube ČT sport Velo Fokus na Spotify Diskutujte s nami na Discorde!

(3.7.2024) Mala to byť klasická šprintérska etapa, no na jej konci bol historický moment. Zo svojho rekordného 35. etapového triumfu sa radoval aj v podcaste mnohokrát odpisovaný Mark Cavendish, čím prekonal Eddyho Merckxa. O tom, čo to znamená a čo tomu predchádzalo sa Filip ako hosť Velo Fokus podcastu ČT Sport rozprával so Sašou Tinkovou a Petrom Musilom z ČT Sport. Video verziu podcastu nájdete na Youtube ČT sport Velo Fokus na Spotify Diskutujte s nami na Discorde!

*Podporte podcast Dobré ráno v aplikácii Toldo na ⁠sme.sk/extradobrerano. Nórov sme síce zdolali, na postup medzi elitnú osmičku to však nestačilo. Tak pre slovenskú reprezentáciu dopadli minuloročné majstrovstvá sveta v hokeji, ktorých dejiskom boli fínske Tampere a lotyšská Riga. Tentoraz sa ľadové majstrovstvá konajú u susedov v Česku a slovenský tím pod vedením Craiga Ramsayho si dokáže podľa mnohých športových odborníkov poradiť aj s tvrdou konkurenciou. Aké sú naše šance na výhru, aké zaujímavosti sprevádzajú tohtoročné majstrovstvá a kto je jasným favoritom turnaja? Eva Frantová sa v podcaste Dobré ráno pýta športového redaktora portálu Sportnet Miloslava Šebelu. Zdroje zvukov: RTVS, TA3, TV Markíza, IIHF, ČT Sport, Hokej.cz, JOJ 24 Odporúčanie: Ak by ste sa chceli na tému hokejových majstrovstiev naladiť ešte viac, odporúčam utorkovú časť podcastu PRESSko, v ktorej sa téme venuje Pavol Rajtár z Hokejportal.sk a Tomáš Prokop z Denníka Šport. – Všetky podcasty denníka SME nájdete na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ sme.sk/podcasty⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ – Odoberajte aj audio verziu denného newslettra ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ SME.sk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ s najdôležitejšími správami na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ sme.sk/brifing⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ – Odoberajte mesačný podcastový newsletter nielen o novinkách SME na ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠sme.sk/podcastovenovinky⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  – Ďakujeme, že počúvate podcast Dobré ráno.

(7.12.2023) Česká cyklistika si prešla generačnou výmenou. Štybarovsko-Kreuzigerova generácia je pomaly minulosťou a nastupujú noví pretekári a pretekárky. Aký má za sebou rok česká cyklistika, na aké talenty by sme sa mali pozerať a prečo by sme vo februári všetci mali ísť do Tábora hovorí v rozhovore Vojtěch Jírovec z ČT Sport a podcastu Velofokus. Diskutujte s nami na Discorde! Najlepším kávovým partnerom CykloPodcastu je slovenská pražiareň kávy COFFEEIN. Odporúčame! Hlavným mediálnym partnerom je magazín o cyklistike Cycling-Info.sk. Mediálny partner je RoadCycling.cz.

(17.10.2023) Peter Sagan, ktorého kariéra viac ako dekádu elektrizovala nielen Slovensko nedávno ukončil svoju cestnú kariéru. Preto sa oplatí na ňu pozrieť rôznou optikou a zhodnotiť veľké množstvo úspechov a zopár pádov trojnásobného majstra sveta. Epizóda vznikla v spolupráci s Velo Fokus podcastom ČT Sport, moderoval ju Vojtěch Jírovec a okrem nášho Adama Beňa v nej hosťovali aj ex-profesionál František Paďour a novinárka Saša Tinková. Velo Fokus na Spotify Diskutujte s nami na Discorde! Najlepším kávovým partnerom CykloPodcastu je slovenská pražiareň kávy COFFEEIN. Odporúčame! Hlavným mediálnym partnerom je magazín o cyklistike Cycling-Info.sk. Mediálny partner je RoadCycling.cz.

(19.7.2023) Po 17. etape bol CykloPodcast v kompletnej zostave hosťom českého podcastu Velo Fokus od ČT Sport. Moderuje Vojtěch Jírovec. Video verziu podcastu nájdete na Youtube ČT sport Velo Fokus na Spotify Diskutujte s nami na Discorde!

V sobotu startuje letošní ročník největšího cyklistického závodu světa - Tour de France. Rozsahem, významem i sledovaností jde o jednu z nejprestižnějších sportovních událostí planety. Jak se jí daří vypořádat s aktuálními výzvami, jako je environmentální zátěž v časech stále naléhavější klimatické změny? Proč v silniční cyklistice vidíme tak malou diverzitu? A dokázala se zbavit stínu dopingové minulosti?Host: Vojtěch Jírovec - redaktor webu ČT SportČlánek a další informace najdete na webu Seznam ZprávySledujte nás na sociálních sítích Twitter a Instagram. Náměty a připomínky nám můžete psát na e-mail zaminutusest@sz.cz

Otevíráme zlatou bránu olympijského turnaje, jsme olympijští vítězové!“ To je jedna z nejznámějších hlášek komentátora Roberta Záruby. Ovšem ne jediná. Jaká je vaše nejoblíbenější? Podcast o MS v hokeji a fungování ČT Sport si můžete poslechnout nyní. Našimi hosty byli Robert Záruba a Jiří Ponikelský, moderuje Martin Rachmann. Právě teď na Spotify a Youtube!

V noci z neděle na pondělí proběhl už 56. ročník Super Bowlu, každoročně nejsledovanější události ve Spojených státech. Co to znamená pro Ameriku a jak se mění zájem o americký fotbal v Česku? O tom se v dnešním vydání E15 Castu bavil Nikita Poljakov s Jiřím Kalembou, šéfeditorem webu ČT Sport a nadšencem do amerického fotbalu.  www.e15.cz

Take a deep dive into the future of Tandem Diabetes. In December, the company laid out an ambitious 5-year plan to update software, move to a smaller pump and ultimately a tubeless version. Company leaders say they want to think even bigger and we're talking to Chief Strategy Officer Elizabeth Gasser. We'll go through the short term changes Tandem has in the pipeline like the tiny Mobi pump and talk about philosophy and more. Tandem R&D Presentation (slides)  Tandem R&D Presentation (replay)  This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *DEXCOM*   Stacey Simms  0:00 Diabetes Connections is brought to you by Dexcom. Take control of your diabetes and live life to the fullest with Dexcom and by Club 1921 where Diabetes Connections are made. This is Diabetes Connections with Stacey Simms. This week, a deep dive into the future of Tandem diabetes. That company laid out an ambitious five-year plan to update software, move to a smaller pump and ultimately move to a tubeless version. company leaders say they want to think even bigger.   Elizabeth Gasser  0:37 we have thermostats that manage our home temperature for us. We have self-driving cars we have on demand consumption services that you know, help us get our groceries and plan our meals. Come on. We should demand that level of ease of use in what we're doing here as well.   Stacey Simms  0:54 That's Tandem Chief Strategy Officer Elizabeth Gasser. We'll  go through the short term changes Tandem has in the pipeline like the tiny Mobi pump, she'll answer a bunch of your questions. We'll talk about the philosophy of the company moving forward, and more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show, I am only so glad to have you here. You know, we aim to educate and inspire about diabetes with a focus on people who use insulin. back in December Tandem made a big splash with their very first research and development presentation. If you haven't seen that, I highly recommend that it is rather long, but it's definitely worth checking out. I'll link that up in the show notes. And you can always find out more at diabetes connections.com. But in this R&D presentation, they laid out a very ambitious five-year plan for the company, which we're going to go through and talk about in detail today. Quick date check for you This interview was taped on January 10 2022. And we're releasing it on January 25 2022. So as of right now, the FDA has not approved anything new for Tandem no Mobile bolus that is in front of the FDA, and we'll talk about that and so much more. There were a few questions I didn't have time to get to or that you sent in after the interview. So I sent those to Tandem and I will come back after the interview. I'll update you and answer what I can also after the interview, if you are a health care provider, a diabetes educator and endocrinologist if you work in those offices. And a very specific question for you. Please come back. I'll make it quick. But I need some information. And I know you will can help me. Okay. My guest this week is Tandem Chief Strategy Officer Elizabeth Gasser she says Call me Liz. So I do. Her background isn't in diabetes, it is in strategy and corporate development, working at Qualcomm in their internet services division and at open wave systems, the world's leading Mobile browser provider at that time, and we talk about what it's like to come from that world to this one, I think it's really important to kind of get an idea for these individuals, you know who they are, who are making these decisions that affect so many of us. And of course, we go through that 10 to five year plan product by product.   Liz, welcome to Diabetes Connections. Thank you so much for joining me, we have a lot to talk about today. Thanks for being here.   Elizabeth Gasser  3:24 Oh, my pleasure. I'm excited to chat.   Stacey Simms  3:27 There are a lot of items that Tandem announced in December, there's a lot to go through there. But I wonder if we could start kind of by backing up a little bit I've heard that you Tandem is kind of talking about being less of a hardware company, right, the pump, which will always be there in some way, shape, or form. But thinking more about the software, can we step back a little bit from the products here and talk a little bit more about kind of the philosophy or the vision? Oh, happy   Elizabeth Gasser  3:53 to and if you've watched our R&D day, you'll you'll know that I do enjoy expanding on this particular topic. You know, as with any connected device, the minute you take a piece of hardware, and you give it a cellular connection or or a Wi Fi connection or a connection to the Internet, you've opened up the potential way to do an awful lot of creative things with both data but also with software, it really opens up the potential for continuous update functions and capability. And then also the ability to pull and push data back and forth from a device and and once you've done that, you you really crossed into that that world of the Internet of Things which requires you to be both an excellent hardware company, because you're managing the device, the functions of that device. It's touchpoints through connectivity, but it also requires you to be an excellent software company along the way. And if you look at the Tandem journey over the past five to seven years, you really do see the company's products moving down that pathway. Of course, the pump remains front and center for us it you know, the delivery of insulin is what we do. It's how we bring that therapy benefit to our users. But you also see a start to do things like the ability to update the pump software itself that unlocks new features and functionalities, including the algorithms which we can now continuously update, it allows us to update the different types of devices we integrate with, you'll see we've obviously moved from supporting Dexcom, G5, two, G6, and we're moving to G7. That's all done through software updates. And so it's really hard to be in this space and to be talking about connectivity and connected devices without also embracing the fact that you really are a software company and have to be incredibly good at it to deliver the value that you want to deliver to your customer base.   Stacey Simms  5:59 I do remember years ago, our first pump and I say our work has been he was to when he got it. So it was definitely it was a group effort. But it was the Animas pump. And then a few years or months who remembers after he got that there was an update, where you could bolus from the remote meter. But we had to wait until our insurance would cover until we were up for a new pump. We had to wait I think three and a half years before we could get that. And so when we switched over to Tandem, I think we had the pump for a month when we there was a software update. So it really has changed. And to your point it is it is really remarkable to see that. Let's talk about, as you mentioned, the R&D presentation and some of what's in development. And of course, the usual disclaimer, I am sure that a lot of what we're going to talk about here is in development, it is not FDA approved. So there are limitations, I'm sure about what you can and cannot speak about. And if you can't answer something we totally understand. But let's just jump on in and kind of go through a list here. My listeners are extremely interested in getting some kind of update on the bolus by phone, which is in the FDA hands. But I have to ask you about   Elizabeth Gasser  7:07 I figured you would like the the world is obviously a very unpredictable place these days, not least when it comes to projecting FDA timelines. That said, we still feel very confident and we're planning on an early 2022 approval. So I can't say much more than watch this space. But we're still leaning into the timelines. We talked about it R&D Day and looking at getting this much requested feature to our user base as soon as we can.   Stacey Simms  7:39 Can you share with the rollout process may be? In other words, will it be a simple update to the T Connect app? Will there be some kind of required or prescription required online patient training?   Elizabeth Gasser  7:49 Yeah, happy to and this this kind of ties to the conversation we were just having about, you know, being a software company, right? The introduction of this feature will be straightforward software updates. And so what does that mean? In practical terms, that means updating the iOS or Android Android application to the newest version, which will have the Mobile bolus capability. And at the same time, making sure you do a pump software update so that both sides of that dialogue can happen. And as part of the pumps software update, which happens through the Tandem device updater. There will be some online training, music click through to make sure that they understand the capabilities that we're introducing. And many of our users will be familiar with how you do that.   Stacey Simms  8:33 Would there be a prescription needed for that kind of feature? A   Elizabeth Gasser  8:36 Mobile bonus? Yeah, no,   Stacey Simms  8:39 this may be a silly question. But can you share any details of what Mobile bolus actually means? In other words, I visioned this as Benny will take the his phone out and have full functionality controlling the pump from the phone. Is that accurate?   Elizabeth Gasser  8:53 Yes or no, in that the primary goal of Mobile bolus is to allow for the delivery of a bolus from the phone. So in that sense, you're absolutely right, it will become for most of the day, the app will be the vehicle through which you can interact with the pump the piece, it won't do his full control of the pump. Meaning when you need to go in and look at changing settings, for example, that's not going to be in the Mobile bolus release. That's something that you don't have to do all the time, and can reasonably be done by taking the pump out and using the user interface on the device. As we get to the movie launch. Obviously, that will not have a screen. And so those control features, what we call full control will migrate into the app as well, for the movie pump.   Stacey Simms  9:46 Of course, yes, that makes perfect sense. I'm not going to let myself get too far ahead because boy do I want to ask you about but to just stay on on Mobile bolus for one one or two more questions, but with Mobile bolus are there other There are features that will be on the phone, obviously, it   Elizabeth Gasser  10:03 will marry with the app that currently exists today, right. And so that that is predominantly today, a secondary display tool allows you to see all of the things that are going on with the pump allows you to see blood glucose readings allows you to see insulin on board allows you to see the insulin delivery that you've conducted through the day. And so all of those features will remain. And the focus here really is on augmenting it with the ability to deliver a bolus from the phone. And so that sort of feels like it downplays. No. But it's incredibly, it's an incredibly exciting augmentation, and one that we think is an incredibly important first step towards that for control. Because it is the hardest use case, we have to get that absolutely right.   Stacey Simms  10:49 Will that have share and follow? Is that something that you're working on for down the line? Or is that something that may come sooner? So really   Elizabeth Gasser  10:56 good question. And we do recognize that share follow is incredibly important to our users and their families. Were continuing to look at where explicit share and follow capabilities for on our roadmap and what the best path to implementing that is, in large part because there's a diversity of CGM follow options out there, including our own Sugarmate application, which which can be used for blood glucose monitoring in a follow capacity. And so we don't have roadmap dates to share at this point in time, just know that we're sensitive to figuring out what the best possible implementation is for our customers here. And we want to make sure we're getting as much experience as we can, in the meantime, really understanding how to do good follow. And as I say, we're getting some of that through the Sugarmate app that we're operating, which actually just went live with the Dexcom real time API, right. And so there's a little complexity to thinking through what the best implementation model is. We're working on it and watch this space.   Stacey Simms  12:00 Well, since you brought up Sugarmate, I have to ask with Sugarmate, which is if it's not clear, Tandem owns as you said, many people don't realize that is sugar beet, something that people could use, kind of as a bit of a workaround for a Tandem share and follow or Sugarmate only displays Dexcom data right now.   Elizabeth Gasser  12:18 So today, sugar is explicitly a CGM companion application. It displays data from the Dexcom CGM. Over time we're looking at what features need to be added to that to ensure it delivers the best value proposition to our users. Really interesting   Stacey Simms  12:33 stuff. All right, you segwayed beautifully into my question about Dexcom. How soon after Dexcom G7 is FDA approved, do anticipate it being available on the x two and again, is that a simple software update?   Right back to our conversation, but first Diabetes Connections is brought to you by Dexcom. just about to talk about there. And one of the most common questions I get is about helping children become more independent. You know, those transitional times are very tricky elementary school to middle school middle to high school you get but I'm talking about using the Dexcom has made a big difference. For us. It is not all about sharing follow. I mean, that is very helpful. But think about how much easier it is for a middle schooler to just look at their Dexcom rather than do four to five finger sticks at school, or for a second grader to show their care team the number before Jim at one point, but he was up to 10 finger sticks a day and sometimes more and not having to do that makes his management a lot easier for him. It's also a lot easier to spot the trends and use the technology to give your kids more independence. Find out more at diabetes connections.com and click on the Dexcom logo. And now back to Liz I just asked about tandems planned integration of Dexcom G7 when it is approved and released.   Elizabeth Gasser  13:53 We are intending to implement Dexcom G7 With both pump models so that means X2 and that means Mobi, down the road, our current goal, and this remains our goal is to deliver that within a quarter of FDA approval of the G7. And in terms of how they gets rolled out. I mean, it's very consistent with the software conversation we were just having right. The beauty of the software model is you know, as that gets approved, and as the implementation is ready, we'll be making it available to customers through a simple software update.   Stacey Simms  14:26 Let's move on and talk about the December R&D presentation where this large plan, I think very ambitious and exciting was laid out for the next five years. And we've already mentioned a couple of the products. We're going to go through it in some more detail, but I am curious kind of, you know just what it was like that day and if you didn't see it or hear it, I can link up the video. I'm assuming that it's still up there. But I guess I'm asking this is what were you all talking about that day? There were so many people involved in the presentation, kind of doing handoffs and saying, here's the product, here's the software, here's the philosophy, it had to be a big deal. Tandem had to be a lot of relief when all the technology worked. And everybody got their presentations through with it. You were done.   Elizabeth Gasser  15:07 Oh, absolutely. I couldn't agree more with that sense of it was momentous. And certainly at the end of it, we're all pretty tired. But no, it was, it was exhilarating, too. And I think, you know, we spend a lot of time because of because we're in a regulated space, we spend a lot of time talking day to day about the here and now the stuff that's approved, the stuff that's in market, and the reality is a lot of what we shared R&D day we've been working on for a while now. And you know, some of it's been skunkworks. Some of it's been more formal programs, you know, you just ticking along. And it was really exciting to have a vehicle to share a lot of that thinking and a lot of that innovation that we get to see day in day out. But we don't always get to tell the world about because of the rules and regulations in our space.   Stacey Simms  15:59 Alright, let's talk about it as much as we can. You've mentioned Mobi several times, this had been referred to and I had been told this was not gonna be the name. So we didn't know that. But this had been formally referred to as T-Sport. Now, it is Tandem Mobi. Can you go through the features? Can you go through what this product is?   Elizabeth Gasser  16:19 Absolutely. Where to start? First at it. It's the world's smallest durable pump. So if you're familiar with with the X2, it's half the size, that's really small, durable, four year lifespan hardware. So that in and of itself is exciting. In terms of where we go with the software on top of Mobi, it's going to support Control IQ. So same great algorithm that's in market today, it will be deployed on on both pumps in the same way. And so we get to bring that algorithm across the entire portfolio when Mobi launches, it will be controlled by phone as we were talking about earlier. And that means full control at this point in time, obviously, because there's no screen on the device itself. So what does that mean? Everything you need to do to interact with the pump settings, whether it's bolusing, whether it's looking at your statistics throughout the day, that will come from the phone, it will be charged inductively, which that you know, not something you don't really focus on. But that's that's pretty cool. With we're getting used to wireless charging for all of our consumer electronics devices not having to hunt around for a cord to plug it in. That's what we're doing with with Mobi as well. It'll sit on a little charging station, very easy, very straightforward, less pieces to worry about on pump bolus button. And this one we think is a little differentiated. Certainly in the on body arena, I think it will be the only one only pump out there of this size that has the option to fall back to a button push on the pump just to make sure because obviously, when you are interacting with your pump solely through a phone, we need to build in some measure of failsafe fallback, right if you find himself without the phone, and needs to bolus. And then lastly, waterproof. We're going to support waterproof capabilities through IPX8, which I think is pretty competitive. So lots of stuff packed into a really, really tiny device.   Stacey Simms  18:25 I'm sorry, what is IPX? Eight mean?   Elizabeth Gasser  18:28 The best way to articulate it, it's really just the standards we comply with and IPX eight means fully waterproof, you'll be able to swim and shower with it.   Stacey Simms  18:36 One question about Mobi is I'm trying to visualize how it connects. My understanding is that it uses the standard pumping fusion set that like my son's Tslim currently uses, is that correct? It just sits closer to the body.   Elizabeth Gasser  18:51 That is correct. The Mobi pump will work with the Tandem portfolio of infusion sets. And with the Mobi pump launch, we will also be introducing a shorter infusion set that four or five inches long, that allows for greater diversity of wear options.   Stacey Simms  19:09 I'm so fascinated to see how this works because I'm a very visual person. So he could put it on like my son could put it on his arm and it kind of dangles off. Does it also stick to the body in a way? Or does it just kind of hang there on the tubing, the tiny tubing   Elizabeth Gasser  19:24 work, we're working on the accessories to allow for a diversity of wear options, whether the belt clips or sleeves or a body worn adhesive patch through which you can that you can pop the pump into. So there's a variety of places you can push   Stacey Simms  19:39 it interesting, alright. And like I said, I will link up so you can you can really dial down if you want to and see all of the features of everything we're going to talk about. But just for time limitations, we're not able to go through every single thing. Let's move on to the T slim x three that seemed to be next in the pipeline. What is that?   Elizabeth Gasser  19:55 x three. That's the next iteration for the T slim X To pump. And really the focus there is to continue really honing the capabilities of the T slim form factor, right. And so we recognize that over time t slim continues to play a role in the portfolio, many of our users will continue to want a pump with a built in user interface. And so really the x three programs emphasis is on further developing the processor capabilities of that device, looking at battery life, looking at durability, reliability, looking at wireless software update capabilities, really to make sure that the T slim x two kind of line has continued vibrancy as part of the portfolio over time. And we're making the appropriate investments to support the diversity of software and user interfaces that we want to bring to the portfolio at large. So   Stacey Simms  20:54 right now, it sounds like the changes you're talking about aren't something that, you know, I would look at the pump and say that is significantly different, right? Or that works completely did you've changed at all, it's making small improvements and things that the user, frankly, may not notice? Or will they're, you know, things will just run better, like you said battery life, that sort of thing. Are there significant changes that you could think of that would be coming to the pump itself?   Elizabeth Gasser  21:16 Oh, no, that's absolutely right. I think this one's a little fun for me, because I come from the consumer electronics space, originally and spent 20 years you know, working on phones. And as you think about the types of releases, you do with consumer electronics, year to year, a lot of them are under the hood, that it's really focused on making it connect better, giving it more horsepower, making the battery last longer. And those things aren't always visible on the surface to a user, but may manifest through the quality of the user experience they get from interacting with that device.   Stacey Simms  21:50 The next product is Mobi tubeless. We've talked about what Mobi is, I'm assuming this means know to tell me a little bit about Mobile tubeless. This is   Elizabeth Gasser  22:01 a certain creativity and the naming convention there isn't so   Stacey Simms  22:06 we shouldn't laugh. It's a very big deal. It's a very big deal.   Elizabeth Gasser  22:09 No, I say that affectionately. And look, it's back to the conversation we were having on kind of the Mobi, shorter infusion set and different Bodywear options, more ways to air Mobi, right, we recognize that not everyone ultimately wants a pump with a tube. And so we've been pushing ourselves to say, okay, how can we improve the wearability and the wear option, so that we're reaching the broadest possible base of customers here. And, and this one's kind of an example of the things that we've had in the hopper for a while that not everyone gets to see, we took a little trip in the Wayback Machine and dusted off some of our earliest thinking on movie here. And maybe a tubeless infusion site option has been in our minds for a while. And so we felt it was the right time to bring that idea back to look at how to make it a reality as we get closer to the official launch of Mobi. And so this sits in the roadmap for Mobi as additional ways to utilize and engage with the product. And hopefully, it will give users choices, right? Some days, I don't want to wear my pump on my body, I might want to have it in my pocket and connect via a standard infusion site. Other days, I may be a little more active and find a really need to have a have a tubeless wear option, we get rid of the tube, the goal for us is to satisfy all of those use cases.   Stacey Simms  23:34 And then the last one is the completely disposable patch pump that's in the pipeline. Is this a different form factor than Mobi? Is it a different design? Or is it similar?   Elizabeth Gasser  23:44 So this is a different program? I can absolutely share that. I can't say a whole lot. This is one we want to keep fairly tight under wraps for competitive reasons. But the emphasis there is is very much on miniaturization. Got it. Can we really push the design envelope here on form factor for the device?   Stacey Simms  24:06 You know, it's so interesting. We've been in this community as a family for 15 years. So now you're certainly not as long as many other people but in that time, we've seen and heard a lot of products, right? We've heard about new things coming. We've seen some really great advancements, we see things go away. This is a very ambitious portfolio that we're looking at and five years is it doesn't seem like a long time really certainly as I get older, it seems less than less. Seems everything's going more and more quickly. But a lot can happen in five years is the is the plan here that all of these products will exist together. As you said, you know, the movie tubeless you kind of made it sound like I might be able to take out my Tandem movie with the longer tube and then switch to the tubeless another day is the idea that all of these would exist side by side.   Elizabeth Gasser  24:50 That's a great question, Stacey. I think the best way to answer that is to really reflect on the fact that we do fundamentally believe the day Diabetes space and particularly insulin dependent diabetes is a far more segmented market than every industry analysis would lead us to believe. You know, we often talk about type one and type two, as if those are the only segmentations that are relevant, we do actually think there's various needs, that we should appropriately be segmenting around, including, where preference form factor and user and interface size. And so as we look at the portfolio, we're really looking at how we can satisfy the broadest array of user needs. That may mean there is on occasion, some overlap in functionality between different products that sit in the mix. But the goal is really to provide the right device for the right group at the right time. And so as we think about where we go from here, the roadmap as we have sketched it out, for the 22 to 27 period really is very much about a tube pump offering with a screen, that's Tslim X2, a smaller form factor, more discreet phone operated screen, this option in the form of Mobi and there, the goal really is to create as diverse an array of wear options as we can to satisfy the needs of different user groups and their day to day activities, and then pass that as you think about the idea of a passionate disposable patch that exists as a third category that overtime will, we'll have to see how these different offerings play out with the segments that they're serving, and they are likely to coexist.   Stacey Simms  26:39 So interesting. As we begin to kind of wrap this up, I did have a couple of questions from listeners I wanted to get to, and one of them was about control IQ, frankly, and any changes coming. In other words, we had heard a lot about changing the adjustable, changing the target rates lower than 160 and 180, that they are right now not the target rates. That's when the pump takes action, that kind of thing. And I remember hearing that there was something in front of the FDA, I don't know how much you can share. But can you talk to us about changes coming to control like you, yeah, happy to   Elizabeth Gasser  27:09 talk about the design goals. In terms of control IQ today, it's delivering great outcomes. And in its current instantiation, I think one of the things that's helpful to understand about algorithms is that they're all going to work in different ways. It's like chocolate chip cookie recipes. If you think about it, lots of people have them, but it's how you put the pieces together and in what order and it's the secret sauce that affects how it tastes. Similarly, with algorithms, a lot of it comes down to how you put it together. And it's not always practical to compare from one to another. The real test is, you know, are you getting users to where they need to be in terms of, you know, being able to achieve their time and range goals, for example. So I think it's worth wrapping your head around that idea upfront. Now, having said that, for the control IQ roadmap, our next development frontier really is very much around personalization, and usability. While we're not going to get into very specific, you know, roadmap feature intersections at this time, we're exploring quite a bit here. And Jordan alluded to this a little bit in our R&D Day discussion, part of personalization for us does include exploring lower target ranges, and personalized target ranges, and looking at what it would take to deliver on those capabilities.   Stacey Simms  28:32 Here's a real speculative question that I don't expect you to answer. I'm hearing in the DIY space, that more and more people are coming up with algorithms that don't need meal announcements, or don't even need meal boluses. Is that something that Tandem is working on for an algorithm? Or I guess the real personal question is, could you please Liz, help me because my son forgets to bolus for many meals. He's 17. He's very independent. But oh my gosh, when I see people working on things like that, I just feel like that would be life changing.   Elizabeth Gasser  29:05 Yeah, mail handling unannounced meals on lounge consumption. Yeah, it's the hardest thing to confirm it with the algorithm here. It is fair to say that as part of our ongoing roadmap explorations, we are looking at what it means to improve unannounced meal handling.   Stacey Simms  29:24 I'll take it. I'll take it. Thank you. Another question came up about new infusion sets. And you had mentioned this, you touched on this briefly, but we talked to folks at ConvaTec who make many of the infusion sets and they were talking about longer life improvements to the cannulas or those sorts of things coming to Tandem. Yeah, so we   Elizabeth Gasser  29:46 did talk a little bit about our goals here. During R&D day. You know, it is only one piece of the system but we do recognize infusion set issues can be a real pain point for customers and so we have programs IPs that are ongoing. Some of them are internal driven by us. Some of them are in conjunction with our partners working on a diversity of things. Some of it is extended wear time, which we know is important. But we're also looking at insertion, ease and usability there, we're looking at how to reduce infusion site failures, specifically around occlusions, obviously continuing to look at things like adhesives, reduction of material waste. And so this one, it's a pretty diverse view that we're taking. It's not all necessarily anchored solely in the idea of extended wear, I can't give you any specific breaking news in terms of you know, what we're coming up with and the products we'd like to bring to market. But this one we're paying serious attention to, we recognize that our customers want to see progression here.   Stacey Simms  30:57 Yeah, I have been amazed since day one of pumping, I feel like the infusion sets have, at least for us, and everybody is different. And everybody's skin is different. Everybody's insertion technique is different, which is part of the problem. But you know, I've just been amazed to me, that has always been the weakest link of pumping. And the idea that I'm using pretty much the exact same infusion set that I put on my son's body 15 years ago, just with all the advances that we've had to me, that's the one that needs much more attention. So I'm really, really glad to hear you're working on that. Alright, so this is not a question. But this was a thought that ran through many of the comments. Many people wanted to say, thank you for getting this is terrible. Thank you for getting control IQ through the FDA before COVID. Because oh my gosh, nothing has happened since like, this was approved, what December of 2019. And many people started getting it I think the earliest was January of 2020. And the diabetes community it feels like very little, although there have been there have been approvals. But it feels like everything is moving so slowly now. So I'm sure Tandem is happy about that. But I know the community as well. So I'm not sure if I can even ask you to answer. There's no question there. But thank you.   Elizabeth Gasser  32:05 Oh, I'm not sure there's any good answers there either. Stacey, I certainly applaud the the yeoman's work going on at the FDA to manage through this crisis. And certainly while it's frustrating to have extended approval cycles, and yes, in retrospect, a blessing that we secured approval prior to COVID. I can't do anything but feel respect, admiration and a little bit of sympathy for our friends at the FDA. Yeah. And   Stacey Simms  32:35 again, I don't know if you can answer something like this. Have you heard that they are they're kind of making their way through it just seems like there was such a log jam, I understandably so any feeling any word that they are kind of clearing the deck, so   Elizabeth Gasser  32:47 to speak? I don't think it's my place to comment on my workflow there. I   Unknown Speaker  32:50 tried. You can we do have good   Elizabeth Gasser  32:52 back and forth with the FDA, you communicate with them regularly. And so they continue to engage with the industry constructively, productively.   Stacey Simms  33:02 Alright, before I let you go, you don't live with diabetes, as you said at the very beginning, you know, you come from a software background and that sort of thing. But what is it like to come from that and work in in diabetes, where the work that you do I mean, here I am complaining about infusion sets, and, you know, change the bolus, from what you know, before it reaches 180? You know, we're talking about all of these little things add up to such quality of life issues for people, you know, what does it been like for you to work in this space?   Elizabeth Gasser  33:28 That's a great question. It's one that I think you're the first person to ask me to reflect on. You know, I think it is both sobering and invigorating, sobering because, you know, when you come from a world that's, you know, focusing on clicks and engagement and eyeballs, and consumption of media, you can get lost in the little things, and really stepping back and recognizing just the enormity of what type 1 diabetes is, and the burden it places on people's lives, day to day, and feeling like I can show up to work and even in a little way, help with that. That's sobering and profoundly rewarding. It's also invigorating, because, you know, coming from a consumer electronics environment, you see what's possible with the technology as it exists today, and many of those technologies have not yet come to medical devices in a very fulsome way. And so I certainly get out of bed day in day out wondering how we can help therapy benefit from all of the innovation that is going on, in the consumer electronics world, right. You know, we have thermostats that manage our home temperature for us. We have self driving cars we have on demand consumption services that you know, help us get our groceries and plan our meals. I don't mean to trivialize the differences that are involved in translate I think that to medical devices, but I also think as you look at that and say, Come on, we should demand that level of ease of use in what we're doing here as well. And so that that's profoundly motivating.   Stacey Simms  35:13 That's great. Well, thank you so much for sharing so much information for answering what you could answer. And I hope we talk again soon. My pleasure.   Elizabeth Gasser  35:21 Thank you, Stacey.   Stacey Simms  35:27 You're listening to Diabetes Connections with Stacey Simms more information at diabetes connections.com, including the link to the research and development presentation. If you'd like to watch that or just listen to it, I will link that up over on the website along with the transcription. I really appreciate your patience with the transcriptions. I think we do a great job. But my transcription software doesn't speak diabetes, I try to teach it but it is a little unreliable. That way we go through and try to catch the big stuff. But if you do see anything egregious, or very confusing, please let me know. And I can pretty easily fix that. I want to take a moment and address a couple of the questions that we ran out of time with Tandem or your questions came in late. I'm going to do that in just a moment. But first, I mentioned at the beginning of the show that I had a question for healthcare providers, I have a question for you, I have a favor to ask of you. You may have heard me talk about Club 1921. I mentioned it right at the beginning of the show, I'm only talking about if you're at the end of some of the podcast episodes, and in the Facebook group, we are in beta. It is my new project. It's all about events in the diabetes community nationwide, any type of diabetes anywhere in the United States. I need your help, because it's very easy for me to find the big events, right friends for life, JDRF, even ADA stuff online. What I would like to add to the website, and what I think will be vital to its success are all of the events going on in your hospitals. Almost every hospital has a nutrition program for people with type two, an education program for gestational diabetes, things like that. They can be virtual, they can be in person, but I need to find those programs, I need to get into those hospitals, I need to reach the people who want to add those events. This is not a community calendar, where I hope a couple of groups post their events. And we all go from there. I want this to grow into a site where 1000s of people with diabetes, any type of diabetes, find their community find help find what's being offered. And I know that these hospitals want to connect with these folks. So if you could help me do that point me in the right directions to meet with the association's it doesn't have to be one on one with hospital systems, although that would be great, too. But whatever you think might be a help, I would really appreciate it, you can email me Stacey at diabetes connections.com, you can message me on social media, thank you so much, because this will only succeed if we reach out beyond the community that we are already talking to. So thanks. Okay, let's get to the kind of leftover questions from Tandem, the most common one had to do with international rollout. And I unfortunately, I don't really have any good answers for you. I'll tell you what Tandem said I asked specifically about Australia, I had two people who emailed me asking about what is going on in Australia with the rollout of Control, IQ, nevermind all these other features. And they just said we do not have an update at this time. And then asking about other international markets. So let me read that response in full Tandem says we have launched in a large majority of the international markets, and we're near to medium term focuses on ensuring we work to make our technology broadly available to these customers. We don't have anything to disclose with regard to additional markets at this time. So I know not the answer you were hoping for. I will keep asking on this one. And I do apologize, we are a very US centric podcast because I am US centric. But I appreciate the reminder. And I will try to keep that focused and you know on my list of questions as we move forward with lots of different technology this year. And then I had also asked them about changes to the current controller queue algorithm. I had asked during the interview if it could take action at a lower number than 160, which is where it jumps up to basil and 180 where it gives an auto bolus at 60% of the bolus rate that the person programs in and Liz did answer that question in the abstract, but I wish I had pushed on it. So I followed up because I thought I had heard that Tandem had already submitted a change on that to the FDA. They responded quote, as Liz mentioned in the interview, we are working on personalization features which include lower targets and thresholds. We've begun to engage the FDA and started our design work, but we're not currently providing any of the feature details and quote, I will add this editorial comment. Every pump company I talked to has started out saying we're going to have lower ranges, we're going to have tighter ranges, we're going to have customizable ranges and every time it hits the FDA that kind of starts to change set You know, Omnipod, if you'll go back and listen to the interviews from two or three years ago, they were going to submit with I think it was 80 to 100 as one of their ranges. And that didn't happen they've submitted with higher ranges, just like Tandem did. I think, again, this is my speculation, I think these will all gradually come down. But if you are looking now for tighter control with these hybrid closed loops, you might want to go the DIY route. Although if you keep your pump in sleep mode, you know you're sleeping beauties with Tandem it's trying to keep you at like one 12.5 The whole time you just have to remember to bolus which works beautifully for some people, and not at all for the person in my house.   Okay, before I let you go quick look ahead. Of course in the news is every Wednesday we do that live on Facebook, and YouTube and I added LinkedIn this week. My goodness, we're also live on Instagram a little bit later, still can't do all of that at once we're working on it. And then I turned that into an audio podcast episode that is released on Fridays, upcoming longer format shows we'll cover more technology including a new pump called Sigi. We've also got some really interesting community interviews. What is it like right now when you live with type one, but you also live with another autoimmune condition that makes it very difficult to get a COVID vaccine. And I'm going to be talking to some of the Joslin medalists who are this is a theme right living longer with type one and the issues that have cropped up for them that nobody really far, we would have to think about so I'm excited about that and so much more. Thank you as always to my editor John Bukenas from audio editing solutions. Thank you so much for listening. I'm Stacey Simms. I'll see you back here soon until then, be kind to yourself.   Benny  41:48 Diabetes Connections is a production of Stacey Simms media. All rights reserved. All wrongs avenged    

Our top stories In the News this week... Tandem Diabetes shares a big R&D update, laying out their product pipeline for the next 5 years. More stem cell progress, this time from Viactye, a look at another non-invasive CGM claim, big news for Rufus the Bear from JDRF and Stacey spends some time remembering Beyond Type 1 CEO Thom Scher. -- Join us LIVE every Wednesday at 4:30pm EST Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone      Click here for Android Episode transcription below: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. As always, I'm going to link up my sources in the Facebook comments – where we are live – we are also Live on YouTube and in the show notes at d-c dot com when this airs as a podcast.. XX In the News is brought to you by The World's Worst Diabetes Mom, Real life stories of raising a child with diabetes. Winner of the American Book Fest Prize for best new non-fiction. Available in paperback, on Kindle or as an audio book – all at Amazon.com. You can also get a big discount right now at diabetes-connections.com – use promo code celebrate to save $4 XX Our top story, big news from Tandem as they lay out their product line for the next 5 years. Still waiting for FDA approval for bolus by phone.. once that comes through next up is Mobi, that's brand name for what we've all been calling T-Sport until now. Then there will be an X3 pump, then Mobi goes tubeless, then a true disposable patch pump. They also mentioned some software upgrades. A lot can happen in 5 years but exciting to see it laid out. A lot more to come here, we're working on having Tandem on the show soon. https://investor.tandemdiabetes.com/events-and-presentations XX Over at Insulet, CEO Shacey Petrovic says they no longer expect FDA approval for Omnipod 5 in 2021. After all, that's in just a couple of weeks. She spoke at a NASDAQ investor conference and said it's not any kind of problem, just the COVID backlog at the FDA. Petrovic says she is – quote – “eminently confident in our submission.” https://www.medtechdive.com/news/insulet-omnipod-5-delay-fda/610981/   XX More stem cell research news, this time from Viactye. University of British Columbia and Vancouver Coastal Health.  showing that a tiny implant infused with stem cells can help the body produce insulin on its own. Fifteen patients living with Type 1 diabetes participated in the study, which included the insertion of a device the size of a quarter in their abdomen. Each device contained millions of lab-grown cells that were “coached” into becoming insulin producing beta cells. Six months later, the cells had started producing tiny bits of insulin. Next year the team plans to do the procedure without immunosuppression drugs. The ultimate goal to have somebody who stops taking insulin and not have to take any anti-rejection drugs. We first talked to Viactye about this in 2016 – I'll link up that episode. https://www.ctvnews.ca/health/stem-cell-based-treatment-may-help-type-1-diabetes-patients-produce-insulin-canadian-study-1.5694725 XX The White House continues it's push to pass Build Back Better.. focusing a lot this week on the insulin co-pay cap. It's passed the House and if the Senate approves..  government and private insurers have to cap the cost to the patient at $35 for a 30-day supply of insulin. Nothing in the bill for those without insurance. Btw 20 states and DC have passed similar copay limits. I did see late this afternoon on Twitter a few reps who want to change the language to include the uninsured. We shall see.. XX The Free Style Libre 2 App is now available for Android. Approved earlier this year, it's now actually available for download. The Libre 2 version features optional real-time alerts for both low and high glucose levels, without the need to manually scan the sensor to trigger those alarms. You do still need to scan to see the actual number.   https://www.abbott.com/corpnewsroom/diabetes-care/freestyle-libre-2-now-connected-to-your-iphone.html XX Dueling lawsuits from Abbot and Dexcom. Abbot filed suit last week – it's sealed but has to do with a 2014 settlement agreement. That agreement gave the companies cross-licenses to patents related to glucose monitoring. It also included agreements lasting through March 2021 not to sue each other for patent infringement or challenge the patents' validity. We told you back in June of this year that Dexcom filed the first suit, Abbott countered the next day. This seems like an additional legal maneuver in the same case. https://www.reuters.com/legal/transactional/abbott-sues-dexcom-over-glucose-monitoring-patent-settlement-license-2021-12-02/ XX Another entry for the non-invasive blood sugar monitor rumor mill.. K-Watch Glucose smartwatch has a disposable part underneath that features something called “micro-points” that will measure blood glucose. The company says, “Although the wearer might feel some slight pressure, there is no breaking of the skin and therefore no pain.” Not sure those two thoughts really go together – enough pressure can be uncomfortable enough.. but we shall see. The coverage here talks about clinical trials and getting this on the market late next year. I went to the actual clinical trial recruitment site – and I'll link that – it says the trial started in November but it also says it hasn't started recruiting. I know I'm the dream killer with the non invasive monitoring stuff. I do believe it'll get here I promise! But I think the coverage of most of these items Is irresponsibly based on rumors. https://clinicaltrials.gov/ct2/show/NCT05093569 https://www.notebookcheck.net/Painless-continuous-blood-sugar-monitoring-on-the-horizon-for-US-199-thanks-to-the-K-Watch-Glucose-from-PKVitality.582622.0.html XX there's a follow up to a fun story I broke back in 2019 – the merger of Jerry the Bear and Rufus the Bear with Diabetes. Rufus is getting a big  it looks like the Rufus outside with the Jerry the Bear educational interactive stuff and the app. The price is 22-dollars! A far cry from the first version of Jerry which we gave away a few years ago and cost hundreds of dollars. This is really great and I would have absolutely bought it for Benny if it was out when he was little. How'd I break the story? I interviewed the heads of JDRF and Beyond Type 1 when they announced their alliance– and I asked what was going to happen to the bears almost as a joke. They said, nope – they told me then.. only one bear would make it. https://www.prnewswire.com/news-releases/jdrf-announces-the-relaunch-of-rufus-the-bear-with-diabetes-301437309.html XX I want to take a moment and remember Thom Scher – the CEO of Beyond Type 1 who died earlier this week. I went back and listened to that interview we did back in 2019 – the one where he and JDRF told us about Jerry and Rufus… and a lot more. It was one of many times we talked on and off the podcast. I didn't know Thom as well as many others in the diabetes community. We only met in person a few times – first in 2018 at the Diabetes Mine conference and again in 2019 at FFL – where we talked about working together more.. sort of noodling out the possibility of bringing the podcast into the Beyond Type 1 content. Thom was a terrific interview – not afraid to go on the record and very accessible. I remember once I warned him that I had some tough questions from the community about get-insulin dot org because beyond type 1 takes money from the insulin makers. He welcomed it and answered the questions other people would have avoided.  I just read that Thom was 33 when he died. So incredibly young.  He believed in what he did.. he wanted to make life better for people with diabetes. And the world is little emptier without him today. XX Before I let you go, a reminder that the podcast this week is with the executive team at ConvaTec – the people who make infusion sets for tubed pumps, including the new 7-day set for Medtronic. you can listen to wherever you get your podcasts or if you're listening to this as on a podcast app, just go back an episode. Next week it's a first for me, I'm going to do a “favorite things” episode. That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.  

When it comes to diabetes tech, it's the results that speak louder than algorithms. Results driven and starting his career in high-tech, John Sheridan became an authority on tech start-ups leading him to his COO and leader CEO position in Tandem Diabetes Care. His strength has been in leading the commercialization of complex technologies, building the organizations and systems to support business objectives, and predictably delivering financial results. John is all about the patient and the positive experience they're left with. As a leader in diabetes technological innovation, I'm excited to learn from John as the CEO of Tandem Diabetes Care talks tech. [00:01 - 02:49] Opening Segment I introduce John Sheridan Some background on John's story Starting in high-tech  Working for start-ups  Joining Tandem as a COO All about the patient [02:50 - 13:11]  CEO of Tandem Diabetes Care Talks Tech John talks about the user interface of the T-slim Intuitive and easy to use In depth human factors testing  Projections on future dynamics on pumps  Seeing the benefits of Control IQ  Building systems around the pump  Improving user experience Going beyond the algorithm Algorithm is important, results are more important  Current goals and improvements [13:12 - 18:49] Navigating Market Competition  John talks about T-Sport  The difference from Control IQ Moving forward in convenience and discretion  Full mobile control  A response to Omnipod5 A competitive response  Size and aesthetic comparison  Having products that appeal to many  The opportunity for innovation in the market  Moving from pens and needles to a pump  [18:50 - 23:08] Closing Segment Let's talk five years out  Devices will still have a meaningful presence  Close but not quite fully set it and forget it  Quick technological advancements catching the attention of payers Talking about the Companion Acquisition  Tandem's future plans Thank you and please share this  Final Words  Tweetable Quotes: “I think you gotta look beyond the algorithm. The algorithm is important, but you gotta deliver the results.” - John Sheridan  “It's not gonna be this linear advancement of technology. We now have a portfolio of products that appeal to different people. Some people would prefer to continue to use a pump that has an interface on it, some would prefer to have mobile control; the smaller device.” - John Sheridan  “There's a number of opportunities that are similar to pens that are out there. I think that right now we're all about trying to increase the penetration rate in the MDI community; we think iteration is going to do that, and I think that pens are going to help.” - John Sheridan Connect with John on https://www.linkedin.com/in/john-sheridan-84302315/%5C (LinkedIn). Go check out https://www.tandemdiabetes.com/ (https://www.tandemdiabetes.com/) to learn more about this leader in diabetes technology.  To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no way a replacement for real medical professionals. All information in this podcast is obtained through reliable sources. Please be aware of our https://diabeticinvestor.com/investment-newsletter-disclaimer/ (Disclaimer). LEAVE, SUBSCRIBE,...

Vi har fået besøg af den danske Fabrizio Romano, der bærer det borgerlige navn Michel Wikkelsø Davidsen.Michel har sin daglige gang på B.T Sport, hvor han er fodboldredaktør og journalist. Med speciale i dansk fodbold og A-landsholdet kan vi derfor heller ikke undgå at zoome ind på Kasper Hjulmands udtagelse frem mod UEFA Nations League.Vi runder også de danske holds europæiske kampagner, hvor vi særligt dykker ned i FCMs chancer for videre avancement.

PODCAST SPARŤANSKÝCH NOVIN 30 | FOTBAL | 19/20–21 Máme pro vás jubilejní třicátý fotbalový podcast Sparťanských Novin. Naším hostem byl již osvědčený Pavel Jahoda z ČT Sport. Podívali jsme se na dva zápasy, které shodně skončily 2:0 pro Spartu, ale průběhem se úplně nepodobaly. Zaměřili jsme se na Adama Karabce, který si v 16 letech odbyl debut v základní sestavě. Vyzdvihli jsme výkony Lukáše Štetiny a zamysleli se nad potřebou přivést v létě pravého stopera. Ale témat bylo mnohem víc. Pavla Jahodu doplňují Honza Šťastný a Martin Tomáš. Moderuje Vláďa Dobrovolný. Příjemný poslech! Obsah: 0:33 – Úvod. 0:50 – Liga po přestávce. Fotbal bez fanoušků. 4:44 – Adam Karabec proti Opavě poprvé v základu. Zlepšená rozehrávka Milana Heči. 15:23 – Vychová strahovská akademie další supertalenty? Role Lukáše Váchy v béčku Sparty. 21:06 – Utkání dvou poločasů na Slovácku. Reakce trenéra Kotala na vývoj zápasu. 31:09 – Výkony Guélora Kangy a situace na přestupovém trhu ve vztahu k jeho setrvání ve Spartě. 36:46 – Výkony Matěje Hanouska a Michala Sáčka na krajích obrany. 40:00 – Výborná forma Lukáše Štetiny a jak ovlivní sparťanské hledání stabilního pravého stopera. 47:00 – Neproduktivita Sparty ze standardních situací. 48:57 – Očekávání od nadcházejícího semifinále Mol Cupu proti Plzni. 55:05 – Návrat části fanoušků na stadiony a důležitost jejich podpory. 57:23 – Spekulace o návratu Miroslava Pelty do vedení Sparty… 1:01:40 – Závěr. Použitá hudba: Hymna AC Sparta Praha Football Crazy - Ole Ole Ole Sound effect from https://www.zapsplat.com

(27.6.2019) Mená ako Roman Kreuziger alebo Zdeněk Štybar pozná asi každý poslucháč nášho podcastu. Ako však vyzerá zvyšok českej cyklistickej scény a ako sa líši od tej slovenskej? O piatich jazdcoch vo World Tour, potenciále Elkov Author, ženskej cyklistike, zmiznutí Leopolda Königa, ale aj najväčších talentoch u našich západných susedov sme sa bavili s českým novinárom Vojtom Jírovcom, ktorý pracuje pre portál ČT Sport a zároveň je jednou tretinou športovej relácie na Rádiu Wave - Tribuna. Foto: Jérémy-Günther-Heinz Jähnick/Wikimedia Commons

É dia de acelerar no Autocast! Neste segundo episódio, os editores Diogo de Oliveira e Julio Cabral, e o repórter Raphael Panaro falam sobre os prós e contras de três dos lançamentos mais importantes de maio: o novo Honda HR-V Touring com motor 1.5 turbo, o Peugeot 2008 reestilizado e o aventureiro Renault Kwid Outsider. No segundo bloco, o tema do debate é o T-Sport, possível crossover baseado no Volkswagen Polo que pode suceder o finado CrossFox em 2020. Ainda descolamos uma brecha para falar do Taos, outro SUV da marca alemã que pode chegar no Brasil. Dê o play e divirta-se nosso bate-papo descolado sobre carros! Edição e produção: Vitor Bernardes

Založili jste facebookový profil vašemu podnikání. A teď jak to udělat, aby se o něm dozvěděli vaši zákazníci. Ještě lépe: jak to udělat, abyste pomocí facebooku přivedli na vaše stránky platící klienty. Dnes už si základní procedury facebookového marketingu zvládne nastavit každý sám. Tato epiuzoda podcastu by vis měla nasměrovat ke správným krokům.  Klíčové informace:  Facebook má nejpokročilejší možnosti z hlediska cílení reklamy na správné uživatele  Facebook stále ještě má smysl využívat jako primární nástroj propagace Počet zadavatelů reklamy se v roce 2017 zvedl na 7 milionů. O pět milionů víc než v roce 2016  Novinky z reklamy:  Televize není mrtvá. Určitě ne, když hrají naši. Úvodní zápas českých hokejových reprezentantů na mistrovství světa na Slovensku proti výběru Švédska sledovalo skoro 1 a půl milionu diváků nad 15 let. ČT Sport tím zaznamenala jednačtyřicetiprocentní podíl z celkové sledovanosti pátečního večera. Ostatní pořady silně zaostávaly. Hokej tedy dál přitahuje diváky k obrazovkám.  Češi mají rádi osobní odběr zboží. Vyplývá to z nového průzkumu mezi domácími spotřebiteli. Téměř dvakrát se od posledního měření zvýšil počet odběrných míst. Co se týče běžného doručení, tak zákazníci většinou očekávají cenu dopravného a balného kolem stokoruny a při nákupu na jeden tisíc korun by byli rádi, kdyby měli doručení zcela zdarma. Byla to ale právě doprava a možnosti jejího doručování, které zákazníkům u nás nejvíc vadí. Nejčastěji potom nejasná doba doručení, která zákazníky nutí setrvat v dlouhých intervalech na jednom místě a čekat na doručovatele.  Cílit na starší se vyplatí. Česká pobočka agentury Ogilvy si nechala vypracovat průzkum, podle kterého má velký smysl a potenciál oslovovat cílovou skupinu padesátníků. Jen je potřeba tomu přizpůsobit celkový produkt. Nejčastěji má dle odpovědí dotazovaných padesátníků smysl oslovovat je s turistikou a cestováním, zdravotnickými službami nebo automobilovým průmyslem. A jako kanály, přes které je oslovovat, vyšly nejlépe Televize a rádio, internet a časopisy. 

Alexander will next month compete in one of the world’s most famous and prestigious street races; the Macau Formula Three Grand Prix. Alexander will be racing with ThreeBond with T-Sport, driving the team’s Nissan-engine Dallara which he drove to victory at the F3 Euroseries race at the Nurburgring in August. He was invited by ThreeBond with T-Sport to compete as a guest driver in the fifth round of the F3 Euroseries Championship, which also allowed the British driver to qualify for an entry at Macau. As winner of the McLaren Autosport BRDC Young Driver of The Year Award in 2008, Alexander is on the fast track to the world of Formula 1. With the interest of Formula 1 teams, along with his superb results, Alexander is currently one of the most promising drivers below Formula 1. Alexander competed in Karting for 8 years, winning numerous National and British Titles, The Monaco Kart Grand Prix, The Parma Industrials Championship and 3 British Grand Prix. Finishing his karting career with Pole at the World championships in 2006, Alexander then adjusted to Cars extremely quickly, finishing 2nd in his first ever race. In 2008 Alexander finished the season 2nd in the championship with 2 wins and 12 podiums to his name. He then went on to win the highly prestigious McLaren Autosport BRDC Young Driver of The Year Award and receive his prize of a test in the McLaren Formula 1 car. In 2009 Alexander moved into the hugely competitive F3 Euro Series. Competing with Mücke motorsport, Alexander scored his maiden pole in round 3 along with his first Podium. Winning once and scoring 4 further podiums, Alexander finished the season in 4th place in the Championship and 2nd placed rookie.